IPF: The opportunity for Prometic’s PBI-4050The numbers affected: • 140,000 people in the U.S. diagnosed with IPF 64% are mild to moderate
The limitations of other drugs:
Current issues with existing products include:
• Slow pulmonary function loss
• Modest effect on slowing disease progression
• No demonstration of reversal
• Require management of side effects
The revenues generated:
Sales forecast in 2020 are expected to exceed $3bn
Prometic’s opportunity:
Approximately 60,000 patients with mild to moderate IPF are not being treated by Esbriet or Ofev. This creates a huge opportunity for PBI-4050.
Prometic’s opportunity:
PBI-4050 has demonstrated superior safety, tolerability and efficacy results to existing products on the market. PBI-4050 reverses fibrosis in six organs: lungs, kidneys, heart, pancreas, liver, and skin.